KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Revenue (2016 - 2025)

Historic Revenue for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $16.7 billion.

  • Pfizer's Revenue fell 592.02% to $16.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 billion, marking a year-over-year decrease of 867.38%. This contributed to the annual value of $63.6 billion for FY2024, which is 684.1% up from last year.
  • Per Pfizer's latest filing, its Revenue stood at $16.7 billion for Q3 2025, which was down 592.02% from $14.7 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Revenue ranged from a high of $27.7 billion in Q3 2022 and a low of $3.3 billion during Q4 2022
  • Over the past 5 years, Pfizer's median Revenue value was $14.6 billion (recorded in 2021), while the average stood at $14.2 billion.
  • In the last 5 years, Pfizer's Revenue plummeted by 8741.98% in 2023 and then skyrocketed by 31022.88% in 2024.
  • Over the past 5 years, Pfizer's Revenue (Quarter) stood at $3.4 billion in 2021, then decreased by 4.65% to $3.3 billion in 2022, then grew by 5.31% to $3.4 billion in 2023, then skyrocketed by 415.49% to $17.7 billion in 2024, then dropped by 5.92% to $16.7 billion in 2025.
  • Its last three reported values are $16.7 billion in Q3 2025, $14.7 billion for Q2 2025, and $13.7 billion during Q1 2025.